These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

750 related articles for article (PubMed ID: 16528532)

  • 1. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
    Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
    Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
    Dragovich T; Mendelson D; Kurtin S; Richardson K; Von Hoff D; Hoos A
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):759-64. PubMed ID: 16847673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
    Faivre S; Raymond E; Boige V; Gatineau M; Buthaut X; Rixe O; Bernareggi A; Camboni G; Armand JP
    Clin Cancer Res; 2001 Jan; 7(1):43-50. PubMed ID: 11205916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
    Ricart AD; Berlin JD; Papadopoulos KP; Syed S; Drolet DW; Quaratino-Baker C; Horan J; Chick J; Vermeulen W; Tolcher AW; Rowinsky EK; Rothenberg ML
    Clin Cancer Res; 2008 Dec; 14(23):7947-55. PubMed ID: 19047127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.
    Rasschaert M; Schrijvers D; Van den Brande J; Dyck J; Bosmans J; Merkle K; Vermorken JB
    Anticancer Drugs; 2007 Jun; 18(5):587-95. PubMed ID: 17414628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
    Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
    Mita MM; Mita AC; Chu QS; Rowinsky EK; Fetterly GJ; Goldston M; Patnaik A; Mathews L; Ricart AD; Mays T; Knowles H; Rivera VM; Kreisberg J; Bedrosian CL; Tolcher AW
    J Clin Oncol; 2008 Jan; 26(3):361-7. PubMed ID: 18202410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
    Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
    Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
    Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
    Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
    Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
    Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of imexon in patients with advanced malignancy.
    Dragovich T; Gordon M; Mendelson D; Wong L; Modiano M; Chow HH; Samulitis B; O'Day S; Grenier K; Hersh E; Dorr R
    J Clin Oncol; 2007 May; 25(13):1779-84. PubMed ID: 17470869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
    ; Fouladi M; Furman WL; Chin T; Freeman BB; Dudkin L; Stewart CF; Krailo MD; Speights R; Ingle AM; Houghton PJ; Wright J; Adamson PC; Blaney SM
    J Clin Oncol; 2006 Aug; 24(22):3678-85. PubMed ID: 16877737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
    Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.